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A B S T R A C T
Bone represents a common site of metastasis from several solid tumours, including breast, prostate and lung
malignancies. The onset of bone metastases (BM) is associated not only with serious skeletal complications, but
also shortened overall survival, owing to the lack of curative treatment options for late-stage cancer.
Despite the diagnostic advances, BM detection often occurs in the symptomatic stage, underlining the need
for novel strategies aimed at the early identiﬁcation of high-risk patients. To this purpose, both bone turnover
and tumour-derived markers are being investigated for their potential diagnostic, prognostic and predictive
roles.
In this review, we summarize the pathogenesis of BM in breast, prostate and lung tumours, while exploring
the current research focused on the identiﬁcation and clinical validation of BM biomarkers.
1. Introduction
Bone metastases (BM) represent a frequent incurable complication
of several malignancies, owing to speciﬁc interactions between cancer
cells and the bone microenvironment that make it suitable for tumour
cell implantation and growth [1]. Indeed, approximately 70% of pa-
tients suﬀering from advanced breast or prostate malignancies develop
BM during the course of the disease [2,3], with or without disease at
other sites, while skeletal involvement characterizes approximately
30–40% of lung cancer (LC) patients [4].
Depending on the primary tumour, BM may exhibit a prevalent
osteolytic or osteoblastic pattern, although in most cases a mixed
radiological appearance is detected. Early-stage skeletal lesions are
usually not detectable by current diagnostic tools, and their sensitivity
and speciﬁcity are further limited when disease progression is slow and
mimics non-malignant conditions. Moreover, the radiological appear-
ance of BM may vary over time, both spontaneously and following anti-
resorptive and anti-cancer treatments, and this ultimately complicates
their monitoring [5].
As a consequence, BM are often not diagnosed until symptoms
occur, leading to a signiﬁcant impairment of patients’ quality of life;
furthermore, late BM diagnosis increases the risk of skeletal related
events (SREs) that include hypercalcemia, pathological fractures, spinal
cord injury and unremitting pain requiring radiotherapy and/or sur-
gery. Moreover, the occurrence of one SRE increases the risk of further
SREs and signiﬁcantly impairs overall survival [6].
Physiologically, a delicate balance exists between bone resorption
and osteogenesis, with dysregulation evident during the evolution of
BM [1]. Since bone turnover releases speciﬁc molecules in blood and
urine [7], several attempts have been made to associate variations in
those markers (bone turnover markers, BTM) with BM onset and pro-
gression. In particular, BTM have been extensively investigated for their
potential as diagnostic tools and to provide prognostic information, as
well as to monitor treatment response [7]. At present, the high inter-
and intra-individual variability still represents a limitation to their
routine use.
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Additionally, novel tumour-derived markers are being explored that
predict the risk of development of BM and potentially identify re-
sponders to adjuvant bone-targeted treatments [8,9]. This may lead to
intensiﬁed follow-up in selected patients as well as personalized ad-
juvant therapies, with the purpose to inhibit the onset of BM, which
represent a non-curable condition.
Here, we will summarize the current view on BM pathogenesis in
solid tumours, while exploring the recent advances in the BM bio-
marker ﬁeld, focusing on breast, prostate and lung malignancies.
2. Methods
We ﬁrst conducted an extensive research among previous interna-
tional literature by using the PubMed database and key words such as
“cancer osteotropism”, “bone metastasis biomarkers” and “bone turn-
over markers”, associated with “breast”, “prostate” or “lung cancer”.
Then, we reviewed the references of relevant papers published in
English between 1997 and 2017. Conference abstracts and papers were
identiﬁed by reviewing the websites of relevant international oncology
meetings.
2.1. Physiological bone turnover
Bone turnover is the result of the opposing activities of osteoblasts
and osteoclasts (Fig. 1). The former have a mesenchymal origin and are
deputed to osteogenesis. They ﬁrst synthesize pro-collagen, whose
cleavage at N- and C-terminals produces type 1 collagen and P1NP/
P1CP pro-peptides, respectively; these fragments are released into the
bloodstream and undergo hepatic clearance [5,10]. Then, osteoblasts
secrete bone speciﬁc alkaline phosphatase (BALP) which hydrolyses
pyrophosphate, a physiological inhibitor of bone matrix maturation,
releasing inorganic phosphate [11]. Some osteoblasts are trapped in the
newly formed matrix and become osteocytes, namely dendritic cells
that commute mechanical stimuli into biochemical response, that in
turn regulates bone turnover [12].
Osteoclasts are multinucleated bone-resorbing cells derived from
the monocyte/macrophage lineage. Their erosive activity is based on
the secretion of H+ ions and lytic enzymes, such as proteases and the
tartrate-resistant acid phosphatase type 5b (TRACP-5b). Proteases de-
grade type 1 collagen, thereby releasing N- and C-terminal fragments
(NTX and CTX, respectively) that are detectable in both blood and urine
[13,14].
Several factors contribute to the regulation of bone turnover, in-
cluding the receptor activator of nuclear factor kB-ligand (RANK-L)/
RANK/osteoprotegerin (OPG) axis. RANK-L belongs to the tumour ne-
crosis factor (TNF) cytokine superfamily and is produced by osteoblasts
and stromal cells. RANK-L stimulates osteoclast diﬀerentiation and
maturation by interacting with its receptor RANK, expressed by pre-
osteoclasts; excessive bone resorption is prevented by OPG, an osteo-
blast-derived soluble decoy receptor for RANK-L. A number of pro-os-
teoclastogenic (e.g. interleukin-1, IL-1; IL-6; macrophage colony sti-
mulating factor, M-CSF) and anti-osteoclastogenic (e.g. IL-4, IL-18 and
interferon-β) cytokines contribute to regulate the balance between bone
resorption and osteogenesis [15], together with the hormones involved
in calcium homeostasis. Indeed, vitamin D on one hand enhances bone
resorption to increase calcium bioavailability, while on the other reg-
ulates the synthesis of bone matrix component such as osteocalcin,
osteopontin and BALP. Parathyroid hormone (PTH) and calcitonin exert
mutually opposite eﬀects, with the former stimulating bone resorption
and the latter enhancing osteogenesis [13].
Both estrogens and androgens have a predominant anabolic eﬀect
on the skeleton. Estrogens increase osteoblast number and activity,
while inhibiting osteoclast maturation. Androgens exert not only direct
eﬀects on the growth plate, but also indirect regulatory activity, since
they are converted to estradiol through the aromatization process [16].
2.2. The metastatic process and the bone microenvironment
The development of metastasis has been traditionally interpreted as
the consequence of a late-stage detachment of cancer cells from the
primary site, their subsequent intravasation into blood and lymphatic
vessels and extravasation in distant organs. This process was considered
stochastic and merely mechanical, with the ﬁrst site reached by cancer
cells regarded as the most likely metastatic site, due to tumour cell
entrapment in small sized vessels [17]. In this context, the cells capable
of escaping host immune response would ﬁrst develop micrometastases
and then macrometastases in months or even years, depending on the
balance between tumour dormancy and proliferation [18].
More recently, the primary tumour has turned out capable to release
exosomes, growth factors (e.g. transforming growth factor-β, TGF-β;
vascular endothelial growth factor, VEGF; placental growth factor,
PlGF) and cytokines (e.g. TNF-α) that are able to recruit bone marrow
derived cells (BMDC). BMDC increase vascular permeability, promote
the extracellular matrix remodeling and modulate immune suppression
to create the pre-metastatic niches, providing suitable microenviron-
ments for cancer cell nesting and survival [19] (Fig. 2).
Additionally, epithelial cancer cells undergo a morphological and
Fig. 1. Physiological bone turnover. Bone turnover physiologically results from the
opposite activities of osteoclasts and osteoblasts. The former derive from the monocyte/
macrophage lineage and exert a bone resorptive function, through the secretion of H+
ions and enzymes, such as TRACP-5b. Osteoclastogenesis is enhanced by pro-osteoclas-
togenic cytokines (e.g. M-CSF, IL-6, IL-1). During bone erosion, type 1 collagen undergoes
proteolytic cleavage which results in the release of degradation peptides (NTX, CTX, PYD,
DPD), that are measurable in blood and urine. Conversely, osteoblasts have a mesench-
ymal origin and are deputed to osteogenesis. In particular, they synthesize pro-collagen
whose cleavage at N- and C-terminals produces type 1 collagen, P1NP and P1CP peptides.
Osteoblasts secrete also BALP which is necessary for the mineralization of bone matrix.
Some osteoblasts become osteocytes, namely dendritic cells acting as mechano-transdu-
cers. Bone turnover is regulated by the RANK-L/RANK/OPG axis. Indeed, osteoblasts and
stromal cells release RANK-L that, by binding its receptor RANK expressed by pre-os-
teoclasts, promotes their diﬀerentiation in osteoclasts. OPG partially inhibits this process,
in order to prevent excessive bone resorption. Similarly, sex hormones exert a pre-
dominant anabolic eﬀect. Adapted from D’Oronzo et al. 2015 [95]. Abbreviations: bone
alkaline phosphatase (BALP), C-terminal fragment (CTX), deoxypyridinoline (DPD), in-
terleukin-1 (IL-1), interleukin-6 (IL-6), macrophage colony stimulating factor (M-CSF), N-
terminal fragment (NTX), osteoprotegerin (OPG). pro-collagen type 1 C-terminal pro-
peptide (P1CP), pro-collagen type 1 N-terminal propeptide (P1NP), pyridinoline (PYD),
receptor activator of nuclear factor kB (RANK), receptor activator of nuclear factor kB-
ligand (RANK-L), tartrate-resistant acid phosphatase type 5b (TRACP-5b).
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functional remodeling (the so called epithelial-to-mesenchymal transi-
tion, EMT), to improve their migration capability and invasiveness.
EMT is characterized by the acquisition of a spindle-like shape and the
loss of intercellular junctions, accompanied by the down-regulation of
epithelial markers (e.g. E-cadherin and cytokeratin) and the acquisition
of mesenchymal ones (e.g. N-cadherin, ﬁbronectin and vimentin) [20].
In order to explain the tropism of tumours for speciﬁc sites, Stephen
Paget suggested that tumour cells (seeds) are more likely to metastasize
towards a favorable environment (soil), able to support their growth
[21]. According to this hypothesis, one would expect that tumours
arising in paired organs (e.g. breast and lung) would easily generate
metastases in the contralateral site, but this phenomenon is not fre-
quently observed in clinical practice [22,23].
This theory has been further developed, showing that cancer orga-
notropism is driven by mutually attracting chemokine ligands and re-
ceptors, expressed by stromal and tumour cells, respectively. Indeed,
bone-homing tumour cells overexpress the C–X–C motif chemokine
receptor 4 (CXCR-4), whose ligand (C–X–C motif chemokine ligand 12,
CXCL-12) is secreted by stromal cells, including those residing in bone.
Other chemokine axes are involved in the bone-homing process (i.e.
CXCR-3/CXCL-10 and CXCR-6/CXCL-16) [1], as well as the calcium
sensing receptor (CaSR), expressed by advanced primary breast cancer
(BC) [24] that is apparently responsible for the calcium-induced mi-
gration of BC cells in vitro [25].
Although a huge number of disseminated tumour cells (DTC)
reaches the bone marrow, only a few of them successfully interact with
the stroma, due to the expression of integrins [26]; in particular, αvβ3
and αvβ5 recognize and bind bone matrix proteins, while α4β1 inter-
acts with the vascular cell adhesion molecule-1, expressed by bone
marrow stromal cells [27–29]. Hence, DTC enter a state of dormancy
and acquire the typical features of bone-residing cells (osteomimicry),
in order to escape both cytotoxic treatments and immune response,
until the microenvironment becomes suitable for their outgrowth
months or, more usually, years later [1].
Once DTC start proliferating, osteolytic or osteoblastic BM may
arise. The former, frequently associated with breast and lung tumours,
derive from the establishment of a vicious cycle in which cancer cells
secrete pro-osteoclastogenic factors (e.g. TNF-α, IL-8 and PTH related
protein, PTH-rP). The enhanced bone resorption releases several ma-
trix-stored growth factors (e.g. TGF-β; insulin-like growth factor, IGF;
platelet-derived growth factor, PDGF) that further promote cancer cell
proliferation [26]. On the other hand, prostate cancer (PC) BM are
usually osteoblastic, due to the release of bone morphogenetic proteins
(BMPs), TGF-β and ﬁbroblast growth factor (FGF) that enhance the
diﬀerentiation and activity of osteoblasts [15]. However, in most cases
osteolytic and osteoblastic bone lesions coexist, suggesting the partial
overlapping between those pathogenic mechanisms [30].
2.3. Application of bone turnover markers to the management of osteotropic
tumours
Osteogenesis and bone resorption are both associated with the
physiological release of phase-speciﬁc BTM, whose blood and/or urine
levels reﬂect bone turnover and have been investigated as potential BM
biomarkers (Table 1) [31].
“Bone formation” markers include P1NP and P1CP that are released
in the circulation during pro-collagen cleavage, as well as BALP, pro-
duced by osteoblasts and critical for the maturation of bone matrix. On
the other hand, “bone resorption” is accompanied by type 1 collagen
degradation and the release of several collagen fragments, including not
only CTX and NTX, but also pyridinoline (PYD) and deoxypyridinoline
(DPD) that contribute to the mechanical stabilization of the protein.
Other bone resorption markers are represented by the osteoblast-de-
rived factors RANK-L and OPG, and the osteoclast-derived enzyme
TRACP-5b. All the above-mentioned proteins are detectable in serum,
while the peptides deriving from the degradation of type 1 collagen are
Fig. 2. Establishment of osteolytic bone metastases. The onset of bone metastases is
driven by the primary tumour through the recruitment of bone marrow derived cells. The
latter promote the creation of a “pre-metastatic niche” by remodeling the extracellular
matrix, exerting immune suppressive function and enhancing vascular permeability.
Thanks to the up-regulation of speciﬁc chemokine receptors, some cancer cells migrate
towards the bone niche, where they are able to survive for long periods in a quiescent
state, until local and systemic conditions become suitable for the metastasis outgrowth.
Thus, cancer cells alter the physiological bone turnover by releasing CKs that promote
osteoclastogenesis and bone erosion. This phenomenon frees bone matrix-stored GFs
which in turn promote cancer cell proliferation and perpetuate this vicious cycle. Adapted
from D’Oronzo et al., 2017 [96]. Abbreviations: growth factors (GFs), cytokines (CKs).
Table 1
Bone turnover biomarkers and potential clinical applications.
Biomarker Abbreviation Potential clinical application References
Bone formation markers
Bone alkaline phosphatase BALP Diagnosis of BM from solid tumours [34,42]
Prognostic role in the presence of BM from solid tumours [97]
Prognostic role during BTA treatment [44,45,48]
Prediction of response to atrasentan in PC [50]
Pro-collagen type 1 N-terminal pro-peptide P1NP Diagnosis of BM from BC and PC [32–34,36,37]
Pro-collagen type 1 C-terminal pro-peptide P1CP Diagnosis of BM from PC [38]
Prediction of response to atrasentan in PC [50]
Bone resorption markers
C-telopeptide of type 1 collagen CTX Diagnosis of BM from PC and LC [38,41]
N-telopeptide of type 1 collagen NTX Diagnosis of BM from solid tumours [38,41,89]
Prognostic role in presence of BM from solid tumours [97]
Prognostic role during BTA treatment [44–48]
Prediction of response to atrasentan in PC; prediction of response to ZA [49,50]
Pyridinoline PYD Prediction of response to atrasentan in PC [50]
Tartrate resistant acid phosphatase TRACP Diagnosis of BM from BC [32,34]
Cross-linked carboxy-terminal telopeptide of type 1 collagen ICTP Diagnosis of BM from LC [41]
Receptor activator of nuclear factor KB-ligand/osteoprotegerin RANK-L/OPG Diagnosis of BM from BC [35]
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also measurable in urine [10].
The next section will summarize the potential clinical applications
of BTM in the management of bone-homing malignancies.
2.4. Diagnosis of bone metastases
Several studies have investigated the potential role of BTM in the
diagnosis of BM from solid osteotropic tumours. In the BC setting,
serum levels of TRACP and P1NP were reported to be signiﬁcantly in-
creased in the presence of BM, with the highest concentration of the
latter observed in patients with more than seven skeletal lesions
[32,33]. In a recent prospective study, Lumachi and coworkers eval-
uated the accuracy of BTM in the detection of BC-related BM and
achieved the highest value (82%, AUC = .889, 95% CI .798–.981)
when combining BALP with P1NP and TRACP-5b [34]. On the other
hand, another recent study focused on the RANK-L/OPG ratio that was
found signiﬁcantly increased in BC patients with BM. When considering
a cut-oﬀ value≥ .14, the sensitivity and speciﬁcity were 73% and 72%,
respectively [35].
In PC patients, two studies showed a correlation between high
serum P1NP levels and BM occurrence; interestingly, P1NP variations
were detectable approximately eight months before the scintigraphic
evidence of skeletal involvement [36,37]. Other BTM were investigated
in this clinical setting, including NTX, CTX, P1CP and BALP. In parti-
cular, BALP concentration signiﬁcantly correlated with the extent of
BM and was complementary to PSA during the staging of the disease;
this observation suggested that the bone scan maybe unnecessary in a
selected population [38,39].
In the LC setting, urinary NTX (uNTX) levels> 62.5 pmol BCE/
µmol creatinine strongly correlated with skeletal involvement [40],
similarly to the increased serum concentration of CTX β isomer (β-CTX)
and another peptide deriving from type 1 collagen degradation, namely
cross-linked carboxy-terminal telopeptide of type 1 collagen (1CTP)
(p< .001 in both instances) [41].
A meta-analysis involving 3268 patients with solid tumours showed
that, in the presence of BM, serum BALP (sBALP) was signiﬁcantly
higher, as compared to patients without bone lesions
(41.50±26.61 µg/L vs 14.49±5.52 µg/L, p< .05) [42]. Another
meta-analysis that included 14 studies and 1279 patients, demonstrated
the existence of a signiﬁcant correlation between serum NTX and bone
involvement [43].
Although promising, these results are characterized by sub-optimal
speciﬁcity, sensitivity and diagnostic eﬃciency at the individual patient
level that limit the clinical value of BTM for the diagnosis of BM in
routine clinical practice.
2.5. Prognostic role of bone turnover markers
Several retrospective analyses investigated the association between
BTM levels and clinical outcome, among patients with BM undergoing
anti-resorptive therapies [7].
In particular, sBALP and uNTX levels were assessed in 1824 patients
treated with zoledronic or pamidronic acid for BM from diﬀerent ma-
lignancies; high sBALP signiﬁcantly correlated with the occurrence of
SREs, especially in PC patients, while moderate-high uNTX was asso-
ciated with a two-fold increase in risk of skeletal complications
(p< .001 in both instances) [44]. In parallel with these observations,
Brown et al. described a signiﬁcant correlation between the risk of SREs
and the evidence of high sBALP and uNTX at baseline in bispho-
sphonate treated patients, when exploring data coming from the same
placebo-controlled phase III trials of zoledronic acid in advanced can-
cers [45].
Conversely, normal NTX at baseline correlated with a signiﬁcant
reduction in the risk of death and pathological fractures (40% and 52%,
respectively; p< .0001 in both instances), in patients with BM treated
with zoledronic acid. Moreover, patients whose NTX values remained
within the normal range throughout the trial duration (24 months)
exhibited a 40–68% reduced risk of death or skeletal complications (p
≤ .0005), as compared to those with raised NTX levels [46]. Ad-
ditionally, in patients with high baseline levels of NTX, the progressive
normalization of the parameter during the ﬁrst three months of bi-
sphosphonate treatment (as compared to the failure to normalize)
correlated with better survival and less skeletal complications [47].
In support of this, a recent retrospective study has analyzed data
from 5543 patients treated with zoledronate or denosumab for BM and
involved in three phase III trials. sBALP and/or uNTX ≥ median value
(12.6 ng/ml and 10 nmol/mmol, respectively) after the ﬁrst three
months of treatment were associated with disease and BM progression,
together with signiﬁcantly reduced overall survival, as compared to
lower BTM levels (p< .0001 in all instances) [48].
2.6. Role of bone turnover markers in predicting treatment eﬃcacy
The potential role of BTM in predicting the eﬃcacy of bone-tar-
geting agents (BTA) was deduced from the databases belonging to three
zoledronate randomized clinical trials, involving patients with BM from
multiple myeloma or solid malignancies. In particular, patients with
aggressive skeletal disease and baseline NTX ≥ 100 nmol/mmol crea-
tinine, signiﬁcantly beneﬁted from zoledronate treatment, undergoing
a 31% reduction of the risk of death (p = .0028) independently from
the prevention of skeletal complications [49].
More recently, a prospective analysis has involved 778 PC patients
recruited into a placebo-controlled phase III trial of docetaxel with or
without the endothelin-A receptor antagonist atrasentan. The bone-
targeting capability of this drug has been investigated owing to the
emerging role of endothelin pathway in the progression of BM from PC.
The authors evaluated two “bone formation” (BALP, P1CP) and two
“bone resorption” (NTX, PYD) markers, both at baseline and at regular
intervals, describing a correlation between worse survival and the
evidence of high baseline levels and/or progressive increase of each
marker (p< .001). The trial did not meet its primary endpoint, but the
patients with the highest BTM concentration (upper 25th percentile)
beneﬁted from atrasentan in terms of median survival (13 months vs 5
months with placebo; p = .005) [50].
The role of BTM in predicting response to anti-cancer treatments
other than BTA has also been explored. For instance, ALP levels have
been monitored in PC patients with BM receiving abiraterone, over a
median follow-up of 14 months. Some patients underwent an inter-
esting phenomenon, called “ALP bouncing”, characterized by ALP
rising within the ﬁrst 2–4 weeks of abiraterone treatment, followed by
its decline within 8 weeks. Interestingly, the lack of an ALP “bounce”
has turned out to be the strongest predictor of poor overall survival, in
association with the failure in PSA decrease (p< .001) [51].
2.7. Limitations of bone turnover markers
Several limitations still hamper the routine application of BTM as-
sessment. These include patient's features (age, sex, food intake, natural
diurnal variation, liver and/or kidney diseases) and concomitant
treatments interfering with bone turnover, such as the hormone
therapies currently administered to BC and PC patients [31]. Moreover,
BTM levels physiologically undergo seasonal variations that need to be
taken into consideration when interpreting the measurement [10], and
will inﬂuence both the inter- and intra-assay variation coeﬃcients. In
addition to this, sBALP detection is even more diﬃcult because of its
cross-reactivity with the hepatic isoform of the protein [7].
2.8. Bone metastasis biomarkers in solid malignancies
Recent evidence suggests that the early identiﬁcation of patients at
high risk of BM could lead to the adoption of personalized adjuvant
treatments, potentially able to modify the disease evolution, at least in
S. D’Oronzo et al. Journal of Bone Oncology 9 (2017) 1–9
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BC patients [52–54]. Thus, the next sections will summarize the most
recent advances in terms of BM biomarkers, focusing on breast, prostate
and lung malignancies (Table 2).
2.9. Bone metastasis biomarkers in breast cancer
BC is the most frequent tumour in women, aﬀecting annually more
than 460,000 new patients in Europe, with a mortality incidence of
130,000/year [2]. Up to 70% of women with advanced BC develop BM;
these are usually localized to the axial skeleton and demonstrate a lytic
radiological appearance, although osteoblastic and mixed patterns are
not unusual [6].
A retrospective study investigated the correlation between BC or-
ganotropism and the expression of estrogen receptor (ER), human
epidermal growth factor receptor 2 (Her2) and proliferation rate as
assessed by Ki67 staining, analyzed on 263 primary invasive breast
tumours that subsequently resulted in metastases. The study showed
that ER+ Her2- tumours with Ki67 score> 13% were associated with
the highest incidence of BM (87.8%) [55]. Similar results have been
recently described on a series of 490 BC patients, where hormone re-
ceptor positive (HR+) malignancies resulted in skeletal metastases in
up to 72% of patients, while bone-only metastases were detected in
36% of women with luminal A BC [56].
Several attempts have been made to identify the BC “osteotropism
gene signature”, including the one described by Kang and coworkers
who identiﬁed a 102-gene expression proﬁle in a bone metastatic
subpopulation of the MDA-MB-231 BC cell line [57]. Another smaller
signature, including 15 genes with high recurrence (82.4%) in bone-
homing BC, was identiﬁed on a series of 157 primary breast tumours
and included membrane molecules involved in protein binding [58].
Further investigation led to the evidence that IL-1β gene was sig-
niﬁcantly up-regulated in a bone-homing clone of MDA-MB-231 cells,
obtained by seven passages in vivo. Subsequently, in 150 primary breast
tumours screened for IL-1β expression, a signiﬁcant correlation with the
development of BM (p< .0001) was seen [59]. This evidence was fol-
lowed by the pre-clinical evaluation of an IL-1 receptor (IL-1R) an-
tagonist (Anakinra) for the prevention and treatment of BC-derived BM;
1 mg/kg/day treatment reduced the number of bone metastatic mice
compared with placebo (40% vs 90%) and, interestingly, when the drug
was administered before the tumour cell injection, only 10% of the
animals developed BM [60].
Recently, another gene encoding the zinc-ﬁnger protein 217
(ZNF217) has been found to be signiﬁcantly up-regulated in BC tu-
mours developing BM (p = .005), particularly in those with an ER+
phenotype [61].
The application of genomics to BC research led to the evidence of a
copy number variation associated with BM. In both osteotropic BC cell
lines and primary breast tumours, ampliﬁcation of the 16q23 region,
with at least 1.5 copies of the region, normalized to the CEP16 cen-
tromeric probe per cell, was signiﬁcantly correlated with BM occur-
rence (HR = 14.5, 95% I = 6.4 to 32.9, p< .001). This region (16q23)
encodes a transcription factor (v-maf avian musculo-aponeurotic ﬁ-
brosarcoma oncogene homolog, MAF) involved in the regulation of
several genes participating to the establishment of BC BM, such as
PTHrP [62].
As gene expression regulators, small non-coding micro RNAs
(miRNAs) were also investigated as potential BM predictors. In parti-
cular, up-regulation of miR-10b, miR-373 and miR-520c was correlated
with the enhanced migration and invasiveness of BC cells, both in vitro
and in vivo [63,64]. Moreover miR-218, that is physiologically involved
in osteoblast diﬀerentiation, was found to be associated with BC cell
osteomimicry [65]. Recently, miR-214-3p was shown to be signiﬁcantly
overexpressed in BC patients with osteolytic BM. Through a series of in
vitro and in vivo studies, Liu and coworkers demonstrated that miR-214-
3p can stimulate bone resorption by targeting the TNF receptor asso-
ciated factor 3 (TRAF3) [66].
On the other hand, an array-based miRNA proﬁling was conducted
on MDA-MB-231 cell subpopulations with diﬀerent organotropism and
revealed that some miRNAs were able to interfere with the metastatic
process. In particular, miR-126 was shown to inhibit cancer cell pro-
liferation, while miR-206 and miR-335 impaired cell migration and
invasiveness. These miRNAs were down-regulated in bone-homing cells
and, once re-expressed via retroviral transduction, signiﬁcantly coun-
teracted the development of BM in mice. Moreover, a qRT-PCR analysis
performed on 20 primary breast tumours showed that low expression of
any of the three miRNAs was associated with shorter median time to
metastasis [67].
Several proteomic studies have been conducted to identify potential
BM predictive biomarkers. A recent systematic review focused on 14
proteins that were shown to be signiﬁcantly overexpressed in bone-
homing BC cells (including CXCR-4, cadherin-11, osteopontin and bone
sialoprotein, BSP), while the chemokine C-C ligand 2 (CCL2) has been
inversely correlated with BM occurrence [68].
In a recent proteomic analysis, performed on MDA-MB-231 sub-
populations with variable organotropism, macrophage-capping protein
(CAPG) and PDZ domain–containing protein member 1 (GIPC1) were
up-regulated in bone-homing cells, as compared to the parental popu-
lation. To validate these proteins as biomarkers, breast tumour samples
from 724 patients recruited in the AZURE trial, evaluating the role of
adjuvant zoledronic acid in early BC [53], were analyzed. The authors
showed that high expression of both proteins signiﬁcantly correlated
not only with the development of BM (p< .001) but also with the ef-
ﬁcacy of adjuvant zoledronic acid in preventing BM (p = .008) [8].
This means that besides its role in the prognosis of BM, the combined
CAPG/GIPC1 biomarker is predictive of treatment beneﬁt and could
potentially be applied to the selection of patients for adjuvant
Table 2
Potential tumour-derived biomarkers for BM in breast, prostate and lung cancer.
Bone metastasis biomarkers References
Breast Cancer
Genes
Kang's signature (102 genes) [57]
IL-1β [59]
MAF [62]
15-gene signature [58]
(APOPEC3B, ATL2, BBS1, C6orf61, C6orf167, MMS22L, CNS1,
MFAP3L, NIP7, NUP155, PALM2, PH-4, PGD5, SFT2D2,
STEAP3)
ZNF217 [61]
Proteins
ER +, Her2-neu – [55]
CAPG, GIPC1 [8]
CXCR4, cadherin-11, osteopontin, BSP [68]
HR+ [56]
miRNAs
Up-regulated: miR-10b, miR-373, miR-520c, miR-218, miR-214–3p [63–66]
Down-regulated: miR-126, miR-335, miR-206 [67]
Prostate Cancer
Genes
PDGFRα [72,73]
IL-1β [74]
Proteins
IL-1β [74]
CXCR-4 [75]
miRNAs
Up-regulated: miR−154, miR−379 [76]
Down-regulated: miR-143, miR-145, miR-203 [77,78]
Lung Cancer
Genes
CD22, hepatocyte nuclear factor 1 α, adenomatous poliposis coli [89]
Proteins
BSP, CXCR-4, osteopontin, BMP4 [90,91]
Circulating PTH-rP [92]
miRNAs
Down-regulated: miR-33a [93]
S. D’Oronzo et al. Journal of Bone Oncology 9 (2017) 1–9
5
bisphosphonate treatment.
2.10. Bone metastasis biomarkers in prostate cancer
PC is the second most common tumour in European men and aﬀects
annually 420,000 new patients, with approximately 90,000 deaths/
year. In most cases, it is diagnosed over the age of 70 [3], giving rise to
BM in approximately 70–80% of patients with advanced disease, in the
form of osteoblastic lesions [6,69,70].
Several attempts have been made to identify potential prognostic
biomarkers for PC-related BM and a systematic review, analyzing data
from 8644 patients, correlated skeletal involvement with a Gleason
score ≥ 8, serum prostate speciﬁc antigen (PSA) ≥ 20 ng/ml and lo-
cally advanced disease at diagnosis [71]. However, subsequent studies
partially contradicted these results giving rise to a signiﬁcant debate
about the parameters and cut-oﬀ levels to be employed [70].
Pre-clinical studies focused on two subpopulations of the PC3 cancer
cell line (i.e. PC3-ML and PC3-N), characterized by similar chemokine
receptors but diﬀerential osteotropism. In particular, PC3-ML cells were
found to over-express platelet derived growth factor receptor α
(PDGFRα) and this could partially explain their improved capability to
survive in the bone marrow, under the proliferative stimulation pro-
vided by PDGF [72]. Indeed, once PC3-N cells were transduced to over-
express PDGFRα, they underwent a signiﬁcant improvement of the
bone-homing potential; moreover, an anti-human PDGFRα monoclonal
antibody was able to induce a 72% tumour burden reduction in murine
femora and tibiae, as compared to placebo [73].
Interestingly, PDGFRα was found to up-regulate IL-1β; thus, a ret-
rovirus-mediated over-expression of this gene in PC3-N cells was at-
tempted, observing improved bone metastatic capability. On the other
hand, the IL-1β knock down in PC3-ML cells, obtained through a short
hairpin RNA (shRNA), impaired their osteotropism. Finally, 227 PC
samples were screened for IL-1β and shown to be up-regulated in tu-
mours with a Gleason score ≥ 7, as compared to less aggressive ma-
lignancies or healthy prostate samples [74].
In a meta-analysis involving 630 patients from 11 studies, CXCR-4
was identiﬁed as another potential biomarker and shown to be both
more frequently expressed in PC samples, as compared to non-malig-
nant tissue (p< .00001), and correlated with BM development (p =
.003) [75].
miRNAs have also been investigated as potential BM biomarkers,
through expression proﬁling performed on PC cell lines, primary tu-
mours and BM tissues. In particular, miR-154 and miR-379 were found
to be over-expressed, both in vitro and in vivo, in bone-homing PC cells
with mesenchymal properties and enhanced invasiveness [76]. By
contrast, miR-143, miR-145 and miR-203 were all down-regulated in
osteotropic PC cells, compared to the corresponding primary tumours,
as well as in BM samples. Once PC cells were transfected to over-express
those miRNAs, they lost their “mesenchymal-like” features, and this led
to impaired migration capability and invasiveness. miR-203 was also
found to counteract the osteomimicry process through the down-reg-
ulation of osteoblast-derived genes, such as osteopontin, osteocalcin
and Runx-2 [77,78].
Among soluble biomarkers, circulating tumour cells (CTC) have
been widely investigated in PC patients for prognostic purposes. In
particular, several prospective trials established a correlation between
CTC count and clinical outcome [79–84], leading to the deﬁnition of a
cut-oﬀ value, able to diﬀerentiate men with favorable outcome (with≤
4 CTC/7.5 ml) from those with unfavorable prognosis (with ≥ 5 CTC/
7.5 ml). Moreover, de Bono et al. reported that a post-treatment 30%
decline of the CTC count correlated with better overall survival, in
patients treated with abiraterone or chemotherapy [85]. Interestingly,
PC patients with both bone and visceral metastases exhibited the
highest CTC count (median 26, range 0–207), as compared to those
with soft tissue lesions (median 0, range 0–28). However, no correla-
tions were found between CTC count and skeletal tumour burden,
assessed by both bone lesion count (p = .54) and bone scan index (p =
.81) [86]. Further CTC features, besides their number, have been in-
vestigated for prognostic purposes. Indeed, Okegawa et al. have re-
cently described that the expression of epidermal growth factor re-
ceptor, in CTC isolated from castration-resistant PC patients treated
with docetaxel, correlates with shorter overall survival (5.5 vs 20.0
months), as compared to its absence (p< .001) [87].
2.11. Bone metastasis biomarkers in lung cancer
LC is the third most common bone-homing tumour, with approxi-
mately 30–40% of patients developing BM during their lifetime [88].
A retrospective study of 661 patients with non-small cell LC
(NSCLC) showed the presence of BM in 57.7% of cases at diagnosis,
associated with a median overall survival of 9.5 months. In this series,
osteolytic BM were detected in 74.3% of patients, while mixed (14.3%)
and osteoblastic (11.4%) patterns were much less common [4].
Several markers have been investigated for the prediction of BM in
early-stage patients and Zhang et al. have recently identiﬁed, by next
generation sequencing, three genes (i.e. hepatocyte nuclear factor 1α,
CD22 and adenomatous polyposis coli) with high mutation frequency
(> 50%) in NSCLC patients with BM [89].
Among proteins, BSP was associated with BM occurrence by
Scagliotti and coworkers. In particular, the authors screened primary
NSCLC samples for the expression of 10 peptides and then matched the
results coming from bone-metastatic tumours with a cohort associated
with visceral metastasis and another one without secondary tumours.
The immunohistochemical analysis showed a signiﬁcant correlation
between BSP expression and both worse disease outcomes (p = .02)
and development of BM (p< .001) [90].
Later, another immunohistochemical study was conducted on 105
stage III NSCLC samples; four markers involved in BM pathogenesis
(BSP, CXCR-4, osteopontin and BMP4) were included in a molecular
model, established by multivariate logistic regression and then pro-
spectively validated. The model exhibited a prediction sensitivity of
85.7% and a speciﬁcity of 66.7% [91].
Serum levels of cytokines involved in bone resorption were mea-
sured, at the time of diagnosis, in 1149 hypercalcemic LC patients in
order to ﬁnd out a potential circulating biomarker for BM prediction.
Interestingly, PTH-rP concentration higher than 150 pmol/l was asso-
ciated with the presence of hypercalcemia and signiﬁcantly correlated
with both BM incidence (71.4%) and decreased median survival (1.4
months) [92].
More recently, PTH-rP expression in LC cells has been inversely
correlated with the intracellular levels of miR-33a, a physiological in-
hibitor of PTH-rP transcription. Thus, miR-33a could be considered not
only an indirect biomarker of bone resorption but also a potential
therapeutic target, for which further investigation is needed [93].
3. Conclusions
Bone represents a very common site of metastasis, especially from
breast, prostate and lung cancer. The development of BM deﬁnes a non-
curable condition associated with serious skeletal complications and
worsened quality of life.
BM are often not identiﬁed until patients are symptomatic, since
current diagnostic tools have a limited capability to detect early-stage
lesions. This suggests the need for reliable and reproducible means for
the timely identiﬁcation of “high-risk” patients.
To this purpose, a number of pre-clinical and clinical studies have
investigated tumour-derived markers for their potential BM predictive
role, while BTM have been screened as diagnostic and prognostic
markers, as well as for the development of anti-cancer drugs. However,
several limitations currently hamper their routine use in the clinical
practice, thus further investigation for clinical validation is needed
before a change in guideline-based recommendations can be
S. D’Oronzo et al. Journal of Bone Oncology 9 (2017) 1–9
6
anticipated [94].
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